Navigation Links
Cardiogenesis Corporation to Report 2010 Third Quarter Results on November 3rd
Date:10/20/2010

IRVINE, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (OTCQB: CGCP) announced that the company will release results for its third quarter ended September 30, 2010 on Wednesday, November 3, 2010.  The company added that Paul J. McCormick, its Executive Chairman, and William R. Abbott, its Senior Vice President and Chief Financial Officer, will host an investor conference call that day at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to review the company's financial results and business outlook.

The call is open to all interested investors through a live audio broadcast via the Internet at www.cardiogenesis.com.  The call also will be available to investors and analysts by dialing (866) 783-2145 within the U.S. and Canada and (857) 350-1604 from abroad.  The passcode is 25300206.

The webcast will be archived on the company's web site and will be available for playback for seven days beginning shortly after the live webcast.  A telephonic playback of the conference call will be available beginning at 8:00 p.m. Eastern time on Wednesday, November 3, 2010, and continue through 8:00 p.m. Eastern time on Wednesday, November 10, 2010.  The replay can be accessed by calling (888) 286-8010 within the U.S. and Canada and (617) 801-6888 from abroad.  The replay passcode is 55199188.

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis.  The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina.  Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease.

For more information on the company and its products, please visit the Cardiogenesis company website at www.cardiogenesis.com.


'/>"/>
SOURCE Cardiogenesis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
2. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
3. Cardiogenesis Reports Third Quarter 2009 Results
4. Cardiogenesis Corporation to Present at Noble Financial - ONTRACK 2010
5. Cardiogenesis (CGCP) Listing Upgraded to New OTCQB(TM) Market for All U.S. Registered and Reporting OTC Securities
6. Cardiogenesis Corporation to Report 2010 Second Quarter Results on August 4th
7. Cardiogenesis Executive Chairman Paul J. McCormick Updates Commercial and Regulatory Progress in Interview With Wall Street Reporter, Available Online
8. Cardiogenesis Enrolls First Two Patients in Its Feasibility Study of the PHOENIX® Combination Delivery System
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. CEL-SCI Corporation Releases Letter to Shareholders
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
Breaking Medicine News(10 mins):